Presentation and outcome of hepatocellular carcinoma in HIV-infected patients

A U.S.-Canadian multicenter study

Norbert Bräu, Rena K. Fox, Peiying Xiao, Kristen Marks, Zeenat Naqvi, Lynn E. Taylor, Anita Trikha, Morris Sherman, Mark S. Sulkowski, Douglas T. Dieterich, Michael O. Rigsby, Teresa L. Wright, Maria Del Pilar Hernandez, Mamta K. Jain, Gajendra K. Khatri, Richard K. Sterling, Maurizio Bonacini, Catherine A. Martyn, Ayse Aytaman, Josep M. Llovet & 2 others Sheldon T. Brown, Edmund J. Bini

Research output: Contribution to journalArticle

168 Citations (Scopus)

Abstract

Background/Aims: HIV-infected patients now live longer and often have complications of liver disease, especially with hepatitis B or C virus coinfection. Limited data are available on those with hepatocellular carcinoma (HCC). Methods: A retrospective analysis from 1992 to 2005 in 6 centers identified 63 HIV-infected HCC patients. Controls were 226 consecutive HIV-negative HCC patients from four sites. Results: HIV-positive patients were younger than controls (52 vs. 64 years, p < 0.001), more commonly had chronic hepatitis B or C (97% vs. 73%, p < 0.001), were more frequently symptomatic (51% vs. 38%, p = 0.048), had a higher median alfa-fetoprotein level (227 vs. 51 ng/ml, p = 0.005), but a similar mean Child-Turcotte-Pugh score (7.0 vs. 7.5, p = 0.05) and HCC staging score (Barcelona-Clínic-Liver-Cancer stages C + D in 50% vs. 58%, p = 0.24). HCC developed faster in HIV/HCV-coinfected than in HCV-monoinfected patients (mean, 26 vs. 34 years after HCV infection, p = 0.002). HIV-positive patients received proven therapy more often (48% vs. 31%, p = 0.017), but median survival was similar (6.9 vs. 7.5 months, p = 0.44). Independent factors predicting survival were symptomatic presentation (hazard ratio [HR], 0.437; p < 0.001), any proven therapy (HR, 2.19; p < 0.001), diagnosis after 01-Jan-2002 (HR, 1.52; p = 0.010), Barcelona-Clínic-Liver-Cancer stages C + D (HR, 0.491; p < 0.001), AST/ALT ≥ 2.00 (HR, 0.597; p = 0.001), AFP ≥ 400 ng/mL (HR, 0.55, p = 0.003), and platelets ≥ 100,000/mm3 (HR, 0.651; p = 0.012), but not HIV-serostatus (p = 0.19). In HIV-infected patients without HCC therapy (n = 33), median survival was longer with undetectable HIV RNA (<400 copies/mL) than with HIV viremia (6.5 vs. 2.6 months, p = 0.013). Conclusions: HIV-positive HCC patients are younger and more frequently symptomatic and infected with HCV or HBV than HIV-negative patients. Tumor staging and survival are similar. In untreated patients, undetectable HIV RNA independently predicts better survival.

Original languageEnglish (US)
Pages (from-to)527-537
Number of pages11
JournalJournal of Hepatology
Volume47
Issue number4
DOIs
StatePublished - Oct 2007
Externally publishedYes

Fingerprint

Multicenter Studies
Hepatocellular Carcinoma
HIV
Survival
Liver Neoplasms
RNA
Neoplasm Staging
Viremia
Chronic Hepatitis B
alpha-Fetoproteins
Chronic Hepatitis C
Coinfection
Hepatitis B virus
Hepacivirus
Liver Diseases
Therapeutics
Blood Platelets

Keywords

  • Hepatitis B
  • Hepatitis C
  • Hepatocellular Carcinoma
  • HIV
  • Treatment

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Presentation and outcome of hepatocellular carcinoma in HIV-infected patients : A U.S.-Canadian multicenter study. / Bräu, Norbert; Fox, Rena K.; Xiao, Peiying; Marks, Kristen; Naqvi, Zeenat; Taylor, Lynn E.; Trikha, Anita; Sherman, Morris; Sulkowski, Mark S.; Dieterich, Douglas T.; Rigsby, Michael O.; Wright, Teresa L.; Del Pilar Hernandez, Maria; Jain, Mamta K.; Khatri, Gajendra K.; Sterling, Richard K.; Bonacini, Maurizio; Martyn, Catherine A.; Aytaman, Ayse; Llovet, Josep M.; Brown, Sheldon T.; Bini, Edmund J.

In: Journal of Hepatology, Vol. 47, No. 4, 10.2007, p. 527-537.

Research output: Contribution to journalArticle

Bräu, N, Fox, RK, Xiao, P, Marks, K, Naqvi, Z, Taylor, LE, Trikha, A, Sherman, M, Sulkowski, MS, Dieterich, DT, Rigsby, MO, Wright, TL, Del Pilar Hernandez, M, Jain, MK, Khatri, GK, Sterling, RK, Bonacini, M, Martyn, CA, Aytaman, A, Llovet, JM, Brown, ST & Bini, EJ 2007, 'Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: A U.S.-Canadian multicenter study', Journal of Hepatology, vol. 47, no. 4, pp. 527-537. https://doi.org/10.1016/j.jhep.2007.06.010
Bräu, Norbert ; Fox, Rena K. ; Xiao, Peiying ; Marks, Kristen ; Naqvi, Zeenat ; Taylor, Lynn E. ; Trikha, Anita ; Sherman, Morris ; Sulkowski, Mark S. ; Dieterich, Douglas T. ; Rigsby, Michael O. ; Wright, Teresa L. ; Del Pilar Hernandez, Maria ; Jain, Mamta K. ; Khatri, Gajendra K. ; Sterling, Richard K. ; Bonacini, Maurizio ; Martyn, Catherine A. ; Aytaman, Ayse ; Llovet, Josep M. ; Brown, Sheldon T. ; Bini, Edmund J. / Presentation and outcome of hepatocellular carcinoma in HIV-infected patients : A U.S.-Canadian multicenter study. In: Journal of Hepatology. 2007 ; Vol. 47, No. 4. pp. 527-537.
@article{71fcde12be654653a010bd239679d904,
title = "Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: A U.S.-Canadian multicenter study",
abstract = "Background/Aims: HIV-infected patients now live longer and often have complications of liver disease, especially with hepatitis B or C virus coinfection. Limited data are available on those with hepatocellular carcinoma (HCC). Methods: A retrospective analysis from 1992 to 2005 in 6 centers identified 63 HIV-infected HCC patients. Controls were 226 consecutive HIV-negative HCC patients from four sites. Results: HIV-positive patients were younger than controls (52 vs. 64 years, p < 0.001), more commonly had chronic hepatitis B or C (97{\%} vs. 73{\%}, p < 0.001), were more frequently symptomatic (51{\%} vs. 38{\%}, p = 0.048), had a higher median alfa-fetoprotein level (227 vs. 51 ng/ml, p = 0.005), but a similar mean Child-Turcotte-Pugh score (7.0 vs. 7.5, p = 0.05) and HCC staging score (Barcelona-Cl{\'i}nic-Liver-Cancer stages C + D in 50{\%} vs. 58{\%}, p = 0.24). HCC developed faster in HIV/HCV-coinfected than in HCV-monoinfected patients (mean, 26 vs. 34 years after HCV infection, p = 0.002). HIV-positive patients received proven therapy more often (48{\%} vs. 31{\%}, p = 0.017), but median survival was similar (6.9 vs. 7.5 months, p = 0.44). Independent factors predicting survival were symptomatic presentation (hazard ratio [HR], 0.437; p < 0.001), any proven therapy (HR, 2.19; p < 0.001), diagnosis after 01-Jan-2002 (HR, 1.52; p = 0.010), Barcelona-Cl{\'i}nic-Liver-Cancer stages C + D (HR, 0.491; p < 0.001), AST/ALT ≥ 2.00 (HR, 0.597; p = 0.001), AFP ≥ 400 ng/mL (HR, 0.55, p = 0.003), and platelets ≥ 100,000/mm3 (HR, 0.651; p = 0.012), but not HIV-serostatus (p = 0.19). In HIV-infected patients without HCC therapy (n = 33), median survival was longer with undetectable HIV RNA (<400 copies/mL) than with HIV viremia (6.5 vs. 2.6 months, p = 0.013). Conclusions: HIV-positive HCC patients are younger and more frequently symptomatic and infected with HCV or HBV than HIV-negative patients. Tumor staging and survival are similar. In untreated patients, undetectable HIV RNA independently predicts better survival.",
keywords = "Hepatitis B, Hepatitis C, Hepatocellular Carcinoma, HIV, Treatment",
author = "Norbert Br{\"a}u and Fox, {Rena K.} and Peiying Xiao and Kristen Marks and Zeenat Naqvi and Taylor, {Lynn E.} and Anita Trikha and Morris Sherman and Sulkowski, {Mark S.} and Dieterich, {Douglas T.} and Rigsby, {Michael O.} and Wright, {Teresa L.} and {Del Pilar Hernandez}, Maria and Jain, {Mamta K.} and Khatri, {Gajendra K.} and Sterling, {Richard K.} and Maurizio Bonacini and Martyn, {Catherine A.} and Ayse Aytaman and Llovet, {Josep M.} and Brown, {Sheldon T.} and Bini, {Edmund J.}",
year = "2007",
month = "10",
doi = "10.1016/j.jhep.2007.06.010",
language = "English (US)",
volume = "47",
pages = "527--537",
journal = "Journal of Hepatology",
issn = "0168-8278",
publisher = "Elsevier",
number = "4",

}

TY - JOUR

T1 - Presentation and outcome of hepatocellular carcinoma in HIV-infected patients

T2 - A U.S.-Canadian multicenter study

AU - Bräu, Norbert

AU - Fox, Rena K.

AU - Xiao, Peiying

AU - Marks, Kristen

AU - Naqvi, Zeenat

AU - Taylor, Lynn E.

AU - Trikha, Anita

AU - Sherman, Morris

AU - Sulkowski, Mark S.

AU - Dieterich, Douglas T.

AU - Rigsby, Michael O.

AU - Wright, Teresa L.

AU - Del Pilar Hernandez, Maria

AU - Jain, Mamta K.

AU - Khatri, Gajendra K.

AU - Sterling, Richard K.

AU - Bonacini, Maurizio

AU - Martyn, Catherine A.

AU - Aytaman, Ayse

AU - Llovet, Josep M.

AU - Brown, Sheldon T.

AU - Bini, Edmund J.

PY - 2007/10

Y1 - 2007/10

N2 - Background/Aims: HIV-infected patients now live longer and often have complications of liver disease, especially with hepatitis B or C virus coinfection. Limited data are available on those with hepatocellular carcinoma (HCC). Methods: A retrospective analysis from 1992 to 2005 in 6 centers identified 63 HIV-infected HCC patients. Controls were 226 consecutive HIV-negative HCC patients from four sites. Results: HIV-positive patients were younger than controls (52 vs. 64 years, p < 0.001), more commonly had chronic hepatitis B or C (97% vs. 73%, p < 0.001), were more frequently symptomatic (51% vs. 38%, p = 0.048), had a higher median alfa-fetoprotein level (227 vs. 51 ng/ml, p = 0.005), but a similar mean Child-Turcotte-Pugh score (7.0 vs. 7.5, p = 0.05) and HCC staging score (Barcelona-Clínic-Liver-Cancer stages C + D in 50% vs. 58%, p = 0.24). HCC developed faster in HIV/HCV-coinfected than in HCV-monoinfected patients (mean, 26 vs. 34 years after HCV infection, p = 0.002). HIV-positive patients received proven therapy more often (48% vs. 31%, p = 0.017), but median survival was similar (6.9 vs. 7.5 months, p = 0.44). Independent factors predicting survival were symptomatic presentation (hazard ratio [HR], 0.437; p < 0.001), any proven therapy (HR, 2.19; p < 0.001), diagnosis after 01-Jan-2002 (HR, 1.52; p = 0.010), Barcelona-Clínic-Liver-Cancer stages C + D (HR, 0.491; p < 0.001), AST/ALT ≥ 2.00 (HR, 0.597; p = 0.001), AFP ≥ 400 ng/mL (HR, 0.55, p = 0.003), and platelets ≥ 100,000/mm3 (HR, 0.651; p = 0.012), but not HIV-serostatus (p = 0.19). In HIV-infected patients without HCC therapy (n = 33), median survival was longer with undetectable HIV RNA (<400 copies/mL) than with HIV viremia (6.5 vs. 2.6 months, p = 0.013). Conclusions: HIV-positive HCC patients are younger and more frequently symptomatic and infected with HCV or HBV than HIV-negative patients. Tumor staging and survival are similar. In untreated patients, undetectable HIV RNA independently predicts better survival.

AB - Background/Aims: HIV-infected patients now live longer and often have complications of liver disease, especially with hepatitis B or C virus coinfection. Limited data are available on those with hepatocellular carcinoma (HCC). Methods: A retrospective analysis from 1992 to 2005 in 6 centers identified 63 HIV-infected HCC patients. Controls were 226 consecutive HIV-negative HCC patients from four sites. Results: HIV-positive patients were younger than controls (52 vs. 64 years, p < 0.001), more commonly had chronic hepatitis B or C (97% vs. 73%, p < 0.001), were more frequently symptomatic (51% vs. 38%, p = 0.048), had a higher median alfa-fetoprotein level (227 vs. 51 ng/ml, p = 0.005), but a similar mean Child-Turcotte-Pugh score (7.0 vs. 7.5, p = 0.05) and HCC staging score (Barcelona-Clínic-Liver-Cancer stages C + D in 50% vs. 58%, p = 0.24). HCC developed faster in HIV/HCV-coinfected than in HCV-monoinfected patients (mean, 26 vs. 34 years after HCV infection, p = 0.002). HIV-positive patients received proven therapy more often (48% vs. 31%, p = 0.017), but median survival was similar (6.9 vs. 7.5 months, p = 0.44). Independent factors predicting survival were symptomatic presentation (hazard ratio [HR], 0.437; p < 0.001), any proven therapy (HR, 2.19; p < 0.001), diagnosis after 01-Jan-2002 (HR, 1.52; p = 0.010), Barcelona-Clínic-Liver-Cancer stages C + D (HR, 0.491; p < 0.001), AST/ALT ≥ 2.00 (HR, 0.597; p = 0.001), AFP ≥ 400 ng/mL (HR, 0.55, p = 0.003), and platelets ≥ 100,000/mm3 (HR, 0.651; p = 0.012), but not HIV-serostatus (p = 0.19). In HIV-infected patients without HCC therapy (n = 33), median survival was longer with undetectable HIV RNA (<400 copies/mL) than with HIV viremia (6.5 vs. 2.6 months, p = 0.013). Conclusions: HIV-positive HCC patients are younger and more frequently symptomatic and infected with HCV or HBV than HIV-negative patients. Tumor staging and survival are similar. In untreated patients, undetectable HIV RNA independently predicts better survival.

KW - Hepatitis B

KW - Hepatitis C

KW - Hepatocellular Carcinoma

KW - HIV

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=34548331766&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548331766&partnerID=8YFLogxK

U2 - 10.1016/j.jhep.2007.06.010

DO - 10.1016/j.jhep.2007.06.010

M3 - Article

VL - 47

SP - 527

EP - 537

JO - Journal of Hepatology

JF - Journal of Hepatology

SN - 0168-8278

IS - 4

ER -